Combair(100 mcg+20 mcg)/puff

Combair is a fixed-dose combination bronchodilator used, via nebulizer or metered-dose inhaler, for the acute relief of bronchospasm associated with obstructive airway disease.

Established / guideline-supported uses

• Chronic obstructive pulmonary disease (COPD): for patients on a regular bronchodilator who continue to have evidence of bronchospasm and require a second, add-on bronchodilator; also widely used for acute exacerbations of COPD.
• Acute severe asthma exacerbations: guideline-supported add-on use (e.g., in emergency department/hospital settings) when a short-acting beta-2 agonist alone is insufficient — Combair is given together with other standard exacerbation treatment (systemic corticosteroids, oxygen as needed).

Not indicated for

• Maintenance/controller monotherapy of persistent asthma or stable COPD — Combair is a rescue/acute-relief combination and does not replace inhaled corticosteroids, long-acting bronchodilators, or other prescribed controller therapy.
• Initial treatment of mild, infrequent bronchospasm where a single agent is sufficient.

Combair should be used strictly as directed by a physician as part of an overall asthma/COPD management plan.

Salbutamol + Ipratropium combination products typically contain Salbutamol (as sulfate), a short-acting beta-2 adrenergic agonist, together with Ipratropium Bromide, a short-acting muscarinic antagonist (anticholinergic bronchodilator). Common presentations include a nebulizer solution (e.g., salbutamol 2.5 mg/ipratropium bromide 0.5 mg per 2.5–3 mL respule) and a pressurized metered-dose inhaler delivering a fixed dose of each component per actuation.

Exact strengths, per-actuation/per-respule content, and excipients vary by manufacturer and formulation; always check the specific product label of the dispensed brand of Salbutamol + Ipratropium.

Combair is a fixed-dose combination inhaled bronchodilator that pairs a short-acting beta-2 agonist (SABA) with a short-acting anticholinergic/antimuscarinic agent (SAMA). It is used by nebulization or inhaler for rapid relief of acute bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), particularly during acute exacerbations.

By combining two complementary bronchodilator mechanisms, Combair can produce greater or more sustained bronchodilation than either agent alone in appropriate patients, while remaining a rescue/acute-treatment option rather than a long-term controller medicine.

Combination short-acting bronchodilator: short-acting beta-2 adrenergic agonist (SABA) plus short-acting muscarinic antagonist (SAMA); Combair belongs to the respiratory bronchodilator class used for acute asthma/COPD symptom relief.

Salbutamol + Ipratropium combines two distinct, complementary bronchodilator mechanisms:

• Salbutamol is a selective beta-2 adrenergic receptor agonist. It stimulates beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, which relaxes bronchial smooth muscle and relieves bronchospasm within minutes.
• Ipratropium is a quaternary ammonium anticholinergic that competitively blocks muscarinic (M1, M2, M3) receptors in bronchial smooth muscle, inhibiting vagally-mediated bronchoconstriction. Its onset is slightly slower than salbutamol's but its bronchodilator effect is complementary and additive.

Together, the two components of Salbutamol + Ipratropium act on different receptor pathways in the airway, producing bronchodilation with an onset of action within minutes (mainly from the beta-agonist component) and a duration of action of approximately 4–6 hours. Systemic absorption of the ipratropium component is minimal due to its quaternary ammonium structure and poor oral/mucosal bioavailability, limiting systemic anticholinergic effects at recommended doses.

To use Combair correctly:

• Nebulizer solution: Empty the entire contents of one unit-dose vial into the nebulizer chamber immediately before use (discard any unused portion; do not store opened vials). Administer via mouthpiece (preferred) or a well-fitted face mask, breathing normally until the mist stops (usually 5–15 minutes). Avoid spraying or misting the solution into the eyes.
• Inhaler: Shake well before use, exhale fully, place mouthpiece in the mouth with lips sealed around it, and inhale slowly and deeply while pressing down on the canister; hold the breath briefly, then exhale slowly. Rinse the mouth with water after use if directed.
• If using a face mask for nebulization, take care to shield the eyes, as accidental eye contact with Combair can cause acute eye symptoms (see Precautions).
• Do not exceed the number of doses of Combair prescribed or stated on the label; contact a physician promptly if more frequent use is needed than usual to control symptoms, as this may indicate worsening disease.

Combair should be used with caution alongside the following, due to well-recognized interactions:

• Other beta-adrenergic agents (bronchodilators, decongestants): Additive cardiovascular effects (tachycardia, tremor, palpitations) may occur when combined with the beta-agonist component of Combair.
• Beta-blockers (including cardioselective agents and ophthalmic beta-blockers): May antagonize the bronchodilator effect of the salbutamol component of Combair and can precipitate severe bronchospasm; avoid unless clearly necessary and use a cardioselective agent with caution.
• Diuretics (loop and thiazide) and systemic corticosteroids: May potentiate hypokalemia caused by high-dose or frequent use of the beta-agonist component of Combair; monitor serum potassium, particularly in severe exacerbations.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular effects of the salbutamol component; use Combair with caution, or avoid within 2 weeks of MAOI use, unless the potential benefit outweighs the risk.
• Other anticholinergic (antimuscarinic) medicines: Concomitant use with other anticholinergics may have additive anticholinergic effects (e.g., dry mouth, urinary retention, blurred vision) related to the ipratropium component of Combair.

Side effects of Combair arise from its two components and generally reflect beta-agonist and anticholinergic pharmacology. Commonly reported effects include:

• Tremor, nervousness, headache, and dizziness (mainly from the salbutamol component).
• Palpitations, tachycardia (mainly from the salbutamol component; see Precautions for cardiovascular caution).
• Dry mouth, throat irritation, and cough (mainly from the ipratropium component).
• Nausea and dyspepsia.
• Nervous cough or bronchitis symptoms with regular use, particularly in COPD patients.
• Paradoxical bronchospasm (uncommon but serious; see Precautions).
• Blurred vision, eye pain, or pupil dilation with accidental eye contact of nebulized Combair (see Precautions).

Seek medical advice if side effects are severe, persistent, or if any signs of an allergic reaction (rash, swelling, difficulty breathing) occur after using Combair.

There are no adequate, well-controlled studies of Combair in pregnant women. Salbutamol can, in principle, inhibit uterine contractions due to its beta-agonist activity, particularly with systemic exposure. Combair should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted before use, and uncontrolled asthma/COPD itself carries risk to both mother and fetus.

Small amounts of salbutamol and ipratropium may pass into breast milk. Caution is advised, and a physician should be consulted before using Combair while breastfeeding; the benefit of treating maternal bronchospasm is generally considered to outweigh the theoretical risk to the infant, but this should be assessed individually.

The following precautions apply to the use of Combair:

• Paradoxical bronchospasm: Like other inhaled bronchodilators, Combair can rarely cause paradoxical bronchospasm that may be life-threatening. If this occurs, discontinue Combair immediately and treat with an alternative bronchodilator/therapy.
• Cardiovascular effects: The salbutamol component can cause tachycardia, palpitations, tremor, and (rarely) arrhythmias or ECG changes; use Combair with caution in patients with cardiac arrhythmias, ischemic heart disease, hypertension, or hyperthyroidism.
• Eye effects: Avoid spraying or nebulizing Combair into the eyes; accidental contact (more likely with mask nebulization) can cause acute angle-closure glaucoma, eye pain, blurred vision, or pupil dilation. Use a mouthpiece where possible and shield the eyes if a mask is used; patients with narrow-angle glaucoma require particular caution.
• Urinary retention: The anticholinergic (ipratropium) component may worsen urinary retention in patients with prostatic hyperplasia or bladder outlet obstruction; use with caution in these patients.
• Hypokalemia: High-dose or frequent use of the beta-agonist component, especially with concurrent diuretics, corticosteroids, or during severe exacerbations, can cause or worsen hypokalemia; monitor serum potassium in this setting.
• Not a substitute for controller therapy: Combair is a rescue/acute-relief combination and does not replace inhaled corticosteroids or other prescribed maintenance therapy for persistent asthma or stable COPD.
• Worsening disease: Increasing or insufficiently effective use of Combair may indicate deteriorating asthma/COPD control; the treatment plan should be reassessed by a physician promptly.

Overdose of Combair is most likely to manifest through exaggerated effects of the beta-agonist (salbutamol) component, since systemic absorption of ipratropium is minimal. Possible features include marked tachycardia, palpitations, arrhythmias, tremor, headache, muscle cramps, dry mouth, nervousness, hypertension or hypotension, hypokalemia, hyperglycemia, and, in severe cases, seizures. Anticholinergic (ipratropium-related) overdose effects such as dry mouth, blurred vision, or urinary retention are theoretically possible but uncommon given the drug's poor systemic absorption.

If overdose of Combair is suspected, seek immediate medical attention or contact emergency services/a poison control center right away; do not attempt unsupervised home treatment. Management is supportive and may include cardiac monitoring and correction of electrolyte disturbances under medical supervision; a cardioselective beta-blocker may be considered by a physician in severe cases but should be used with caution given the risk of provoking bronchospasm.

Store Combair at room temperature (below 30°C), away from light and moisture. Do not freeze nebulizer solution. Keep the inhaler canister/nebules in their protective pouch or carton until use, discard opened single-dose nebulizer vials after use, and keep out of reach of children.

• Elderly: No specific dose adjustment of Combair is generally required, but elderly patients may be more sensitive to cardiovascular effects of the beta-agonist component and to anticholinergic effects (e.g., urinary retention) of the ipratropium component; monitor accordingly.
• Hepatic or renal impairment: No well-established dose adjustment is required, as systemic exposure with inhaled/nebulized Combair is limited; use with routine caution in severe impairment.
• Cardiovascular disease: Use Combair with caution in patients with arrhythmias, ischemic heart disease, or hypertension (see Precautions).
• Prostatic hyperplasia/bladder outlet obstruction and narrow-angle glaucoma: Use Combair with caution due to the anticholinergic (ipratropium) component (see Precautions).
• Children: See Pediatric Uses.

Combair is intended for acute, as-needed relief of bronchospasm and short-term use during exacerbations, rather than indefinite regular use as a sole therapy. The treatment plan, including how long and how often Combair is used, should be set and periodically reviewed by a physician as part of the overall asthma/COPD management strategy; needing it more often than usual should prompt medical reassessment.

Salbutamol + Ipratropium belongs to two combined bronchodilator classes: a short-acting beta-2 adrenergic agonist (SABA — salbutamol) and a short-acting muscarinic antagonist/anticholinergic bronchodilator (SAMA — ipratropium bromide).

Salbutamol + Ipratropium acts through two complementary mechanisms on airway smooth muscle: the salbutamol component stimulates beta-2 adrenergic receptors, raising intracellular cyclic AMP and relaxing bronchial smooth muscle; the ipratropium component blocks muscarinic acetylcholine receptors, inhibiting vagally-mediated bronchoconstriction and reducing airway mucus secretion. Together, these actions produce greater or more sustained bronchodilation in acute bronchospasm than either mechanism alone provides in many patients.

Safety and efficacy of the fixed-dose combination Combair have not been well established in children, particularly below 12 years of age; pediatric use should be individualized and supervised by a pediatrician or pulmonologist, typically reserved for situations where combined bronchodilation is judged clinically necessary (e.g., acute severe asthma exacerbations in hospital settings), rather than routine first-line use.

When used in children, Combair requires close monitoring for cardiovascular effects (tachycardia, tremor) from the beta-agonist component and for anticholinergic effects from the ipratropium component; correct inhaler/nebulizer technique (using a properly fitted mask, avoiding eye contact) is important to minimize side effects in this age group.